HR Execs on the Move

Astellas Pharma

www.astellas.us

 
Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.astellas.us
  • 1 Astellas Way
    Northbrook, IL USA 60062
  • Phone: 800.888.7704

Executives

Name Title Contact Details
Frank Hudson
Senior Vice President, R&D Finance Profile
Claudia Uchima
Senior Director of Human Resources Profile
Judy Ball
Acting Head of Talent Acquisition Profile
Jennifer Hersom
Director of Talent and Organization Development Profile
Sean Penistone
Senior Director - Learning and Development - Talent and Od Profile

Similar Companies

Torrent Pharma Inc

Torrent Pharma Inc is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rising Pharmaceuticals

Rising Pharmaceuticals is an industry leader in marketing and distributing innovative branded and multi-source prescription and over-the-counter pharmaceutical products.

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia

Atlanta Oral & Facial Surgery

Atlanta Oral & Facial Surgery is a local, trusted dental practice offering expert dentistry in Atlanta, GA. Contact us and schedule your appointment today!

Sanofi

3129 Sanofi SA is a French multinational healthcare company headquartered in Paris, France.